Alkermes plc
ALKSHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeAlkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in. Valued at $8.79B, ALKS is a mid-cap name in its sector. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Market Cap
$8.79B
Beta
0.29
P/E (TTM)
58.58
P/E (Fwd)
32.19
EPS (TTM)
$0.90
EPS (Fwd)
$1.64
ROE
9.4%
ROA
4.7%
Cash
$511.9M
Total Debt
$1.58B
Free CF
$140.6M
52W Change
80.4%
Annual Financials
Cash vs Debt
On the balance sheet, ALKS has $511.9M in cash with $1.58B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $140.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 9.4% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.7% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $1.11B to $1.48B.
ALKS's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ALKS.